Observational Study About Patients Diagnosed With NAFLD

Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.

NCT Number	NCT05625750
Lead Sponsor	Xiangya Hospital of Central South University
Conditions	Nonalcoholic Fatty Liver Disease
Enrollment	500 participants
Start Date	2022-04-27
Primary Completion	2025-04-27 (estimated)
Study Completion	2027-04-27 (estimated)
Updated on ClinicalTrials.gov	2022-11-30